Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 23, 2014Innovative Technology Adds To Company's Leading Portfolio of Treatment Options for Coronary Artery Disease
Continuing to advance the development of innovative treatment options for coronary artery disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European market...
-
Jul 22, 2014Easy to Use Imaging System to Support Planned Intravascular Ultrasound and Fractional Flow Reserve Products
Boston Scientific Corporation (NYSE: BSX) has initiated full commercial launch of the new POLARIS™ Imaging System. This system will support the Boston Scientific family of intravascular...
-
Jul 21, 2014Advanced Bare-Metal Stent Provides Additional Treatment Option for Interventional Cardiologists and Patients
Boston Scientific Corporation (NYSE: BSX) has received FDA approval for the REBEL™ Platinum Chromium Coronary Stent System, the company's latest generation bare-metal stent for the treatment of...
-
Jul 14, 2014European Launch Means Physicians Can Now Choose From Three Available Valve Sizes To Match Patient Anatomy More Precisely
Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European commercial launch of its new 25 mm Lotus™ Transcatheter Aortic Valve Implantation (TAVI) System,...
-
Jul 14, 2014Innovative Technology Strengthens Company's Leading Portfolio of Solutions for Peripheral Vascular Disease
Demonstrating its continued leadership in the development of innovative solutions for peripheral vascular disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Ranger™...
-
Jul 1, 2014
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results, business highlights and outlook for the second quarter ended June 30, 2014 on Thursday,...
-
Jun 11, 2014Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent...
-
Jun 10, 2014Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
-
Jun 4, 2014
Boston Scientific Corporation (NYSE: BSX) has initiated the RESPOND Post Market Registry to assess real world performance of the Lotus™ Valve System. The RESPOND Registry will collect data on...
-
Jun 3, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo 2014 Healthcare Conference on June 17 in Boston, MA. Dan Brennan, executive vice president and chief...
-
Jun 3, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs 35th Annual Global Healthcare Conference on June 10 in Rancho Palos Verdes, CA. David Pierce, senior vice...
-
May 21, 2014Only 1.1 Percent of Patients Experienced Moderate Paravalvular Aortic Regurgitation; No Severe Cases Occurred
Further validating its advanced transcatheter aortic valve implantation (TAVI) technology, the Boston Scientific Corporation (NYSE: BSX) Lotus™ Valve System continued to demonstrate impressive...
-
May 21, 2014EVOLVE Study Data Presented Today at EuroPCR 2014 Also Demonstrate Excellent Safety Profile
Boston Scientific Corporation (NYSE: BSX) reported positive three-year follow-up data for the EVOLVE clinical trial, comparing the safety and performance of the SYNERGY™ Everolimus-Eluting...
-
May 15, 2014Boston Scientific Offers World Class Endoscopy Training at its Paris Institute for Advancing ScienceBoston Scientific Reinforces Its Commitment to Global Education and Innovation
Boston Scientific Corporation (NYSE: BSX) celebrated the opening of a new facility dedicated to endoscopy training within its Institute for Advancing Science in Paris. The ceremony included major...
-
May 15, 2014Acquisition Expected to Strengthen Peripheral Interventions Business and Accelerate Growth in Peripheral Atherectomy and Thrombectomy Categories
In a move to expand significantly its portfolio of leading solutions for peripheral interventions, Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire the...
-
May 10, 2014PREDICt-RM Collaborative Study between Boston Scientific, American College of Cardiology and Yale University Highlights Improved Outcomes in ICD and CRT-D Patients followed with the LATITUDE™ System
Patients using the Boston Scientific Corporation (NYSE: BSX) LATITUDE™ Remote Patient Management system with wireless telemetry demonstrated significantly lower mortality and fewer...
-
May 8, 2014Boston Scientific Shockless Implant Evaluation (SIMPLE) Study Results Presented at Heart Rhythm 2014, the Heart Rhythm Society's 35th Annual Scientific Sessions
A Boston Scientific Corporation (NYSE: BSX) study demonstrated that outcomes for patients with the company's transvenous implantable cardioverter defibrillators (ICD) who received routine...
-
May 8, 2014Advanced Illumina™ 3D Programming Software Provides Highly Significant Pain Relief in Study Patients
New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate the device provided sustained and highly...
-
May 6, 2014Innovative Technology Designed to Treat Intrauterine Fibroids and Polyps
Boston Scientific Corporation (NYSE: BSX) has signed a definitive agreement to acquire IoGyn, Inc., a pre-commercial stage company. The transaction is expected to close within days. IoGyn has...
-
May 6, 2014Global medical solutions innovator seeks to pioneer new research into effective treatments for heart failure and related cardiac conditions
Boston Scientific Corporation (NYSE: BSX) has joined Optum Labs as the Founding Medical Device Partner to help pioneer new research into effective treatments for heart failure and related cardiac...
-
May 5, 2014Broad Set of Data Reinforces Commitment to Advancing Research and Technology in Electrophysiology
Boston Scientific Corporation (NYSE: BSX) will be presenting new data at the 35th Annual Scientific Sessions of the Heart Rhythm Society in San Francisco on May 7-10, highlighting the company's...
-
May 1, 2014Promising Clinical Data to be Presented at Annual Conference
Boston Scientific Corporation (NYSE: BSX) will present select abstracts and clinical data analyses pertaining to key issues in gastroenterology during Digestive Disease Week (DDW®) 2014, May 4-6...
-
May 1, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2014 Healthcare Conference on May 13 in Las Vegas, NV. Susie Lisa, vice president,...
-
May 1, 2014
Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has launched the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent...
-
Apr 29, 2014Company Exceeds Earnings Per Share Guidance on the Strength of Continued Revenue Growth
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.774 billion during the first quarter ended March 31, 2014. This represents 4 percent operational revenue growth (constant currency...